Form 4: Recursion Pharmaceuticals CEO Christopher Gibson Executes Stock Sales Under 10b5-1 Plan
SEC Form 4 Filing
Christopher Gibson, CEO of Recursion Pharmaceuticals, executed sales of Class A Common Stock on October 2nd and 3rd, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Christopher Gibson, the CEO of Recursion Pharmaceuticals, reported changes in beneficial ownership of the company's stock.
- On October 2nd and 3rd, 2024, Gibson converted 40,000 shares of Class B Common Stock into Class A Common Stock.
- Simultaneously, Gibson sold 20,000 shares of Class A Common Stock on each of those days, at prices of $6.16 and $6.08 respectively.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on December 27, 2023.
- Following these transactions, Gibson directly owns 762,656 shares of Class A Common Stock.
- Gibson also indirectly owns shares through LAHWRAN-3 LLC (486,000 shares), LAHWRAN-4 LLC (388,000 shares), and the Gibson Family Trust (67,875 shares).
- He also holds options to purchase a significant number of Class A Common Stock at various exercise prices and vesting schedules.
Sentiment
Score: 5
Explanation: Neutral sentiment. The transactions are part of a pre-planned trading strategy, but insider selling can still create uncertainty.
Positives
- The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.
Negatives
- The CEO selling shares, even under a 10b5-1 plan, could be perceived negatively by some investors.
Risks
- Continued sales by the CEO could put downward pressure on the stock price.
- The market may react negatively to insider selling, regardless of the trading plan.
Industry Context
Insider trading activity is always closely watched in the biotech industry, especially for companies like Recursion Pharmaceuticals that are in a high-growth, high-risk sector. Investors often scrutinize these filings for signals about management's confidence in the company's future prospects.
Comparison to Industry Standards
- Comparing Recursion Pharmaceuticals to similar biotech companies like Exscientia or Relay Therapeutics, insider selling is a common occurrence, especially when executives have pre-arranged trading plans.
- The key difference lies in the magnitude and frequency of the transactions, as well as the overall market sentiment towards the company.
- For example, if a company like Schrödinger (another AI-driven drug discovery firm) reported similar insider sales, the market reaction would likely depend on their recent clinical trial results and overall financial performance.
Stakeholder Impact
- Shareholders may react to the news of insider selling, potentially impacting the stock price.
- Employees may be concerned about the implications of the CEO's stock sales.
Key Dates
| Date | Description |
|---|---|
| 12/27/2023 | Date the Reporting Person adopted the Rule 10b5-1 trading plan |
| 02/04/2022 | Date of stock option grant with an exercise price of $11.4 |
| 10/02/2024 | Date of Class B to Class A conversion and sale of Class A Common Stock |
| 10/03/2024 | Date of Class B to Class A conversion and sale of Class A Common Stock |
| 10/04/2024 | Date of signature on the Form 4 filing |
| 12/30/2030 | Expiration date of stock options with an exercise price of $2.48 |
| 02/01/2033 | Expiration date of stock options with an exercise price of $8.55 |
| 02/04/2032 | Expiration date of stock options with an exercise price of $11.4 |
| 02/09/2034 | Expiration date of stock options with an exercise price of $10.09 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.